NEW YORK – Twist Bioscience said Wednesday after the close of the market that it has priced an underwritten public offering of approximately 4.6 million shares of common stock at $28 per share.
The San Francisco-based synthetic DNA producer expects gross proceeds of about $130 million from the offering, above its previous expectation of $100 million. It will use the funds invest in R&D, scale commercial operations, and expand production capacity.